help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on July 13, 2006, doi:10.1164/rccm.200603-402OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200603-402OCv1
174/7/795    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in AJRCCM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baughman, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baughman, R. P.
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 795-802, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200603-402OC

Original Article

Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement

Robert P. Baughman, Marjolein Drent, Mani Kavuru, Marc A. Judson, Ulrich Costabel, Roland du Bois, Carlo Albera, Martin Brutsche, Gerald Davis, James F. Donohue, Joachim Müller-Quernheim, Rozsa Schlenker-Herceg, Susan Flavin, Kim Hung Lo, Barry Oemar, Elliot S. Barnathan and on behalf of the Sarcoidosis Investigators

University of Cincinnati Medical Center, Cincinnati; Cleveland Clinic, Cleveland, Ohio; University Hospital Maastricht, Maastricht, The Netherlands; University of Essen, Medical Faculty, Ruhrlandklinik Essen, Essen; University of Freiburg Medical Center, Freiburg, Germany; Medical University of South Carolina, Charleston, South Carolina; Imperial College of Science, Technology, and Medicine, London, United Kingdom; Dipartimento di Scienze Cliniche e Biologiche, Università Di Torino, ASO San Luigi, Orbassano (Torino), Italy; University Hospital Basel, Basel, Switzerland; University of Vermont, Burlington, Vermont; University of North Carolina, Chapel Hill, North Carolina; and Centocor, Inc., Malvern, Pennsylvania

Correspondence and requests for reprints should be addressed to Robert P. Baughman, M.D., University of Cincinnati Medical Center, 1001 Holmes, Eden Ave., Cincinnati, OH 45267. E-mail: bob.baughman{at}uc.edu

Rationale: Evidence suggests that tumor necrosis factor (TNF)-{alpha} plays an important role in the pathophysiology of sarcoidosis.

Objectives: To assess the efficacy of infliximab in sarcoidosis.

Methods: A phase 2, multicenter, randomized, double-blind, placebo-controlled study was conducted in 138 patients with chronic pulmonary sarcoidosis. Patients were randomized to receive intravenous infusions of infliximab (3 or 5 mg/kg) or placebo at Weeks 0, 2, 6, 12, 18, and 24 and were followed through Week 52.

Measurements and Main Results: The primary endpoint was the change from baseline to Week 24 in percent of predicted FVC. Major secondary efficacy parameters included Saint George's Respiratory Questionnaire, 6-min walk distance, Borg's CR10 dyspnea score, and the proportion of Lupus Pernio Physician's Global Assessment responders for patients with facial skin involvement. Patients in the combined infliximab groups (3 and 5 mg/kg) had a mean increase of 2.5% from baseline to Week 24 in the percent of predicted FVC, compared with no change in placebo-treated patients (p = 0.038). No significant differences between the treatment groups were observed for any of the major secondary endpoints at Week 24. Results of post hoc exploratory analyses suggested that patients with more severe disease tended to benefit more from infliximab treatment.

Conclusions: Infliximab therapy resulted in a statistically significant improvement in % predicted FVC at Week 24. The clinical importance of this finding is not clear. The results of this Phase 2 clinical study support further evaluation of anti–TNF-{alpha} therapy in severe, chronic, symptomatic sarcoidosis.

Key Words: clinical trial • prednisone • pulmonary function tests • tumor necrosis factor


Related articles in AJRCCM:

Infliximab in Sarcoidosis: More Answers or More Questions?
Eric S. White
AJRCCM 2006 174: 732-733. [Full Text]  



This article has been cited by other articles:


Home page
 Therapeutic Advances in Respiratory DiseaseHome page
R. Kim and K. C. Meyer
Review: Therapies for interstitial lung disease: past, present and future
Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 319 - 338.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
A. U. Wells
Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive
Eur. Respir. J., June 1, 2008; 31(6): 1148 - 1149.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. A. Judson, R. P. Baughman, U. Costabel, S. Flavin, K. H. Lo, M. S. Kavuru, M. Drent, and the Centocor T48 Sarcoidosis investigators
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
Eur. Respir. J., June 1, 2008; 31(6): 1189 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
G H Louie, P Chitkara, and M M Ward
Relapse of sarcoidosis upon treatment with etanercept
Ann Rheum Dis, June 1, 2008; 67(6): 896 - 898.
[Full Text] [PDF]

Home page
 ChestHome page
E. E. Lower, S. Harman, and R. P. Baughman
Double-Blind, Randomized Trial of Dexmethylphenidate Hydrochloride for the Treatment of Sarcoidosis-Associated Fatigue
Chest, May 1, 2008; 133(5): 1189 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. C. Iannuzzi, B. A. Rybicki, and A. S. Teirstein
Sarcoidosis
N. Engl. J. Med., November 22, 2007; 357(21): 2153 - 2165.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. U. Wells, P. Latsi, and W. J. McCune
Daily Cyclophosphamide for Scleroderma: Are Patients with the Most to Gain Underrepresented in this Trial?
Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 952 - 953.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. Moss
Clinical Year in Review II: Interstitial Lung Disease, Sepsis, Pulmonary Infections, and Sleep Medicine
Proceedings of the ATS, September 15, 2007; 4(6): 482 - 488.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. D. Rossman and M. E. Kreider
State of the Art. Lesson Learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis)
Proceedings of the ATS, August 15, 2007; 4(5): 453 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. M. Kahler, P. Heininger, J. Loeffler-Ragg, and H. Vogelsinger
Infliximab Therapy in Pulmonary Sarcoidosis
Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 417 - 417.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. P. Baughman
Infliximab Therapy in Pulmonary Sarcoidosis
Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 417a - 418.
[Full Text] [PDF]

Home page
 ChestHome page
R. P. Baughman, B. K. Sparkman, and E. E. Lower
Six-Minute Walk Test and Health Status Assessment in Sarcoidosis
Chest, July 1, 2007; 132(1): 207 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. U. Wells and C. M. Hogaboam
Update in Diffuse Parenchymal Lung Disease 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 655 - 660.
[Full Text] [PDF]

Home page
 JAMAHome page
S. E. Weinberger
A 47-year-old woman with sarcoidosis.
JAMA, November 1, 2006; 296(17): 2133 - 2140.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. S. White
Infliximab in sarcoidosis: more answers or more questions?
Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 732 - 733.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society 		  ATS Best of the Web